Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf055 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Bailey Hairsine und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centauri Therapeutics Limited, Cheshire, United Kingdom. Hauptthemen laut MEDLINE: Immunotherapy, Gram-Negative Bacterial Infections, Polysaccharides, Gram-Negative Bacteria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Germany's Federal Ministry of Education and Research, Wellcome Trust, UK's innovation agency.
Abstract (Originalsprache)
The current array of traditional antibacterial agents targeting Gram-negative infections are failing to meet the clinical need. Here we present a novel, bifunctional immunotherapy (CTX-09) with the ability to harness endogenous anti-galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (anti-αGal) antibodies to drive immune-mediated clearance of Gram-negative bacteria. In addition, CTX-09 has direct-acting broad-spectrum bactericidal activity equivalent to colistin and meropenem against 1952 Gram-negative clinical isolates. In vitro, CTX-09 demonstrated immune-mediated efficacy through recruitment of anti-αGal antibodies and engagement of antibody effector mechanisms that enhanced bacterial clearance at sub-bactericidal concentrations. In vivo, at sub-bactericidal doses, CTX-09 demonstrated anti-αGal antibody driven clearance of susceptible and multidrug-resistant (MDR) strains. In the presence of anti-αGal antibody, bacterial burden was reduced by >99.9% (3-log10) in neutropenic mouse thigh and pneumonia infection models. This data suggest that CTX-09 or other antibody-recruiting molecules have potential to address the urgent clinical need of patients with gram-negative infections using a novel immunotherapeutic mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centauri Therapeutics Limited, Cheshire, United Kingdom.
- Asgard Therapeutics, Lund, Sweden.
- Immuno-ID Consulting, LLC, Trappe, PA, United States.
- Global Product Development, AstraZeneca, Mölndal, Sweden.
- ADC Therapeutics, London, United Kingdom.
- RQ Biotechnology Limited, London, United Kingdom.
ORCID-Profile: Bailey Hairsine, Emma Leire, Edward Rhodes, Matthew Bushdyhan, David Chapman, Mike Westby, Helen Bright
Förderung
- Germany's Federal Ministry of Education and Research
- Wellcome Trust
- UK's innovation agency
- Wellcome
- HHS
- NIEHS NIH HHS
- Biomedical Advanced Research and Development Authority
- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator
Zitieren
APA
Hairsine, B., Leire, E., Rostam, H. M., Kristian, S. A., Rhodes, E., Johnson, A., Bushdyhan, M., Chapman, D., Pickford, C., Westby, M., & Bright, H. (2025). Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf055
Vancouver
Hairsine B, Leire E, Rostam HM, Kristian SA, Rhodes E, Johnson A, et al. Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf055
BibTeX
@article{Hairsine2025,
author = {Hairsine, Bailey and Leire, Emma and Rostam, Hassan M and Kristian, Sascha A and Rhodes, Edward and Johnson, Adam and Bushdyhan, Matthew and Chapman, David and Pickford, Chris and Westby, Mike and Bright, Helen},
title = {Harnessing endogenous anti-glycan antibodies using a novel, bifunctional immunotherapy to treat gram-negative bacterial infections},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf055}
}
EUVIMED